Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Willett WC Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Fam Med. 1998 May-Jun;7(3):255-60.
Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002 Sep 4;40(5):954-60.
Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M, Rimm EB Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis. 2001 Aug;157(2):495-503.
Chu NF, Spiegelman D, Rifai N, Hotamisligil GS, Rimm EB Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men. Int J Obes Relat Metab Disord. 2000 Sep;24(9):1085-92.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993 Mar 25;328(12):833-8.
Eng PM, Kawachi I, Fitzmaurice G, Rimm EB Effects of marital transitions on changes in dietary and other health behaviours in US male health professionals. J Epidemiol Community Health. 2005 Jan;59(1):56-62.
Eng PM, Rimm EB, Fitzmaurice G, Kawachi I Social ties and change in social ties in relation to subsequent total and cause-specific mortality and coronary heart disease incidence in men. Am J Epidemiol. 2002 Apr 15;155(8):700-9.
Hemenway D, Azrael DR, Rimm EB, Feskanich D, Willett WC Risk factors for wrist fracture: effect of age, cigarettes, alcohol, body height, relative weight, and handedness on the risk for distal forearm fractures in men. Am J Epidemiol. 1994 Aug 15;140(4):361-7.
Hu FB, Willett WC Diet and coronary heart disease: findings from the Nurses' Health Study and Health Professionals' Follow-up Study. J Nutr Health Aging. 2001;5(3):132-8. Review.
Hung HC, Colditz G, Joshipura KJ The association between tooth loss and the self-reported intake of selected CVD-related nutrients and foods among US women. Community Dent Oral Epidemiol. 2005 Jun;33(3):167-73.
Qi L, Rimm E, Liu S, Rifai N, Hu FB Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care. 2005 May;28(5):1022-8.
Rosner B, Willett WC Interval estimates for correlation coefficients corrected for within-person variation: implications for study design and hypothesis testing. Am J Epidemiol. 1988 Feb;127(2):377-86.
Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care. 2004 Jul;27(7):1680-7.
Stampfer MJ, Rimm EB Folate and cardiovascular disease. Why we need a trial now. JAMA. 1996 Jun 26;275(24):1929-30.
Tanasescu M, Leitzmann MF, Rimm EB, Hu FB Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation. 2003 May 20;107(19):2435-9. Epub 2003 Apr 28.
Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005 Mar;81(3):555-63.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.